Monthly Archives: March 2016

Biopharmaceutical News Week 12- 2016

Editor’s Note   Horrible terror attacks did strike in Brussels on March 22 where 31 people were killed and several hundred people were injured. BtoBioinnovation wishes to express its sympathy to all the victims and their families and its strong solidarity with all its Belgian readers and friends.          Zika virus   […]

read more

Biopharmaceutical News Week 11- 2016

Acquisitions /mergers/joint-ventures   Vectura Group (Chippenham, UK) is acquiring fellow Skyepharma (London, UK) in a deal worth $441 million. The move brings together the two companies' complementary inhaled formulation, development regulatory and device expertise to accelerate growth in the inhaled respiratory market.     Business   Roche enters a collaboration agreement with Blueprint Medicines (Cambridge, MA, […]

read more

Biopharmaceutical News Week 10- 2016

Zika virus   In the last edition of the New England Journal of Medicine, a French team reports the first case of a Zika virus associated meningoencephalitis in a 81-year-old man, 10 days after he had returned from a cruise in the South Pacific.   World Health Organization (WHO) Director-General Dr. Margaret Chan said “reports and […]

read more

Biopharmaceutical News Week 9- 2016

Zika virus   French scientists have confirmed that the Zika virus can trigger Guillain-Barré syndrome, a rare disorder in which the body’s immune system attacks the nervous system and triggers paralysis. The study, co-authored by Arnaud Fontanet from the Institut Pasteur in Paris and published in the Lancet Medical Journal, is based on patients’ outcomes from […]

read more

Biopharmaceutical News

Biopharmaceutical News a weekly news in Pharma/Biotech including information about : – Acquisitions / Mergers / Joint-Ventures, – Licensing activities, – Drugs approved and rejected, Drugs at clinical stage, – Sciences & technologies – Medical devices & diagnosis news – Cost, pricing & Market Access – Biotech Events To receive this weekly news Register to our […]

read more